Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy.

LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, Wodtke G, Wilding G, Holen KD.

Cancer Chemother Pharmacol. 2010 Mar;65(4):775-80. doi: 10.1007/s00280-009-1084-8. Epub 2009 Aug 1.

PMID:
19649630
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.

Seymour L, Eisenhauer E.

Cancer Chemother Pharmacol. 2001;47(1):2-10. Review.

PMID:
11221956
[PubMed - indexed for MEDLINE]
3.

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR.

Clin Cancer Res. 2004 Jul 15;10(14):4645-51.

PMID:
15269136
[PubMed - indexed for MEDLINE]
Free Article
4.

Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.

Potter DM.

Stat Med. 2002 Jul 15;21(13):1805-23.

PMID:
12111891
[PubMed - indexed for MEDLINE]
5.

Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status.

Ngeow J, Leong SS, Gao F, Toh CK, Lim WT, Tan EH, Poon D.

Crit Rev Oncol Hematol. 2010 Oct;76(1):53-60. doi: 10.1016/j.critrevonc.2009.10.005. Epub 2009 Nov 24.

PMID:
19939700
[PubMed - indexed for MEDLINE]
6.

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti X.

Eur J Cancer. 2011 Jul;47(10):1468-75. doi: 10.1016/j.ejca.2011.03.016. Epub 2011 Apr 7. Review.

PMID:
21482105
[PubMed - indexed for MEDLINE]
7.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.

Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28.

PMID:
24880774
[PubMed - indexed for MEDLINE]
8.

Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.

Townsley CA, Pond GR, Oza AM, Hirte HW, Winquist E, Goss G, Degendorfer P, Moore MJ, Siu LL.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2141-9.

PMID:
16609027
[PubMed - indexed for MEDLINE]
Free Article
9.

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.

Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA.

Br J Cancer. 1999 Nov;81(5):760-8.

PMID:
10555743
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.

Chen Z, Tighiouart M, Kowalski J.

Contemp Clin Trials. 2012 Sep;33(5):949-58. doi: 10.1016/j.cct.2012.04.007. Epub 2012 Apr 25.

PMID:
22561391
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.

Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.

Strahlenther Onkol. 2003 Oct;179(10):673-81.

PMID:
14566475
[PubMed - indexed for MEDLINE]
12.

Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer.

Firat S, Bousamra M, Gore E, Byhardt RW.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1047-57.

PMID:
11958901
[PubMed - indexed for MEDLINE]
13.

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.

Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP.

Cancer Chemother Pharmacol. 1999;43(1):68-72.

PMID:
9923543
[PubMed - indexed for MEDLINE]
14.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB.

BMC Cancer. 2011 Oct 7;11:432. doi: 10.1186/1471-2407-11-432.

PMID:
21982454
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, Collette L, Rizzo E, Ivy P, Olmos D, Massard C, Lacombe D, Kaye SB, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2050-6. doi: 10.1016/j.ejca.2014.04.030. Epub 2014 Jun 10.

PMID:
24928189
[PubMed - indexed for MEDLINE]
16.

Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.

Gebbia V, Borsellino N, Testa A, Tirrito ML, Ferrera P, Colombo A, Mauceri G, Marrazzo A, Porretto F, Musso M.

Breast Cancer Res Treat. 2003 Jan;77(2):99-108.

PMID:
12602908
[PubMed - indexed for MEDLINE]
17.

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C; European Organization for Research and Treatment of Cancer New Drug Development Group.

Ann Oncol. 2004 Dec;15(12):1816-24.

PMID:
15550588
[PubMed - indexed for MEDLINE]
Free Article
18.

A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.

Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.

Clin Cancer Res. 2001 Dec;7(12):3912-9.

PMID:
11751482
[PubMed - indexed for MEDLINE]
Free Article
19.

Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy.

Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W.

Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):689-96.

PMID:
11020565
[PubMed - indexed for MEDLINE]
20.

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P.

Invest New Drugs. 2011 Jun;29(3):473-80. doi: 10.1007/s10637-009-9381-y. Epub 2010 Jan 15.

PMID:
20082116
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk